Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study
NCT02269969
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Burns
Infection
Interventions
DRUG:
Tobramycin
Sponsor
Sandra Walker